SEC Form 4 · accession 0002014866-26-000011
Indivior Pharmaceuticals, Inc. · INDV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan Preblick
Officer — Chief Financial Officer
Period of report
Jun 8, 2026
Accepted (ET)
Jun 10, 2026 · 6:04 am EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001625297
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2026 | S | 36,000 | $37.70 | D | 284,751 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.